March 29, 2019 10:35 AM EDTUpdated May 26, 08:50 PM

Takeda takes a cautious step into neurological gene therapy, inking preclinical deal with StrideBio

Amber Tong

Saddled with debt and keen to divest non-core business amid the ongoing integration of Shire, Takeda has nevertheless dished out a small sum to beef …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda takes a cautious step into neurological gene therapy, inking preclinical deal with StrideBio

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Take­da takes a cau­tious step in­to neu­ro­log­i­cal gene ther­a­py, ink­ing pre­clin­i­cal deal with Stride­Bio

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Takeda takes a cautious step into neurological gene therapy, inking preclinical deal with StrideBio